品牌现货直购
供应商:我要出现这里




查看所有供应商和价格请点击:

70458-92-3生产厂家

70458-92-3价格

70458-92-3

70458-92-3结构式
70458-92-3结构式

化源商城直购

中文名 培氟沙星
英文名 1-ethyl-6-fluoro-7-(4-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid
中文别名 1-乙基-6-氟-1,4-二氢-7-(4-佳绩-哌嗪基)-4-氧代-3-喹啉羧酸
培氟哌酸
1-乙基-1,4-二氢-6-氟-7-(4-甲基-1-哌嗪)-4-氧代-3-喹啉羧酸
1-乙基-6-氟-7-(4-甲基哌嗪基)-4-氧代-1,4-二氢喹啉-3-羧酸
英文别名 MFCD01685696
3-Quinolinecarboxylic acid, 1-ethyl-6-fluoro-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-
PFLX
Abactal
Pefloxacine
Labocton
Silver Pefloxacin
Pefloxacin
1-Ethyl-6-fluoro-7-(4-methyl-1-piperazinyl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
Pefloxacino
1-ethyl-6-fluoro-7-(4-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
Pefloxacin (USAN)
Pefloxacinum
EINECS 274-611-8
密度 1.3±0.1 g/cm3
沸点 529.1±50.0 °C at 760 mmHg
分子式 C17H20FN3O3
分子量 333.357
闪点 273.8±30.1 °C
精确质量 333.148865
PSA 65.78000
LogP 1.51
蒸汽压 0.0±1.5 mmHg at 25°C
折射率 1.594
储存条件 2-8℃
分子结构

1、 摩尔折射率:85.63

2、 摩尔体积(cm3/mol):252.4

3、 等张比容(90.2K):679.3

4、 表面张力(dyne/cm):52.4

5、 极化率(10-24cm3):33.94

计算化学

1.疏水参数计算参考值(XlogP):无

2.氢键供体数量:1

3.氢键受体数量:7

4.可旋转化学键数量:3

5.互变异构体数量:无

6.拓扑分子极性表面积64.1

7.重原子数量:24

8.表面电荷:0

9.复杂度:545

10.同位素原子数量:0

11.确定原子立构中心数量:0

12.不确定原子立构中心数量:0

13.确定化学键立构中心数量:0

14.不确定化学键立构中心数量:0

15.共价键单元数量:1

更多

1.性状:类白色晶体。

2.熔点(ºC):270--272

3.溶解性:溶于碱性和酸性溶液,微溶于水。

CHEMICAL IDENTIFICATION

RTECS NUMBER :
VB2002000
CHEMICAL NAME :
3-Quinolinecarboxylic acid, 1,4-dihydro-1-ethyl-6-fluoro-7-(4-methyl-1-piperaziny l)-4-oxo-
CAS REGISTRY NUMBER :
70458-92-3
BEILSTEIN REFERENCE NO. :
0567618
LAST UPDATED :
199806
DATA ITEMS CITED :
9
MOLECULAR FORMULA :
C17-H20-F-N3-O3
MOLECULAR WEIGHT :
333.40
WISWESSER LINE NOTATION :
T66 BN VVJ B2 DVQ HF I- AT6N DNTJ D1

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - man
DOSE/DURATION :
1714 mg/kg/21W-I
TOXIC EFFECTS :
Peripheral Nerve and Sensation - paresthesis Peripheral Nerve and Sensation - structural change in nerve or sheath
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - man
DOSE/DURATION :
343 mg/kg/30D-I
TOXIC EFFECTS :
Musculoskeletal - joints Musculoskeletal - other changes
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
16 mg/kg
TOXIC EFFECTS :
Behavioral - hallucinations, distorted perceptions Behavioral - muscle contraction or spasticity
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
>4 gm/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
225 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD - Lethal dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
>50 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
7500 mg/kg/30D-C
TOXIC EFFECTS :
Liver - changes in liver weight Kidney, Ureter, Bladder - other changes in urine composition Blood - changes in serum composition (e.g. TP, bilirubin, cholesterol)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
30 gm/kg
SEX/DURATION :
male 30 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Paternal Effects - testes, epididymis, sperm duct Reproductive - Paternal Effects - prostate, seminal vesicle, Cowper's gland, accessory glands

MUTATION DATA

TYPE OF TEST :
Unscheduled DNA synthesis
TEST SYSTEM :
Rodent - rat Liver
DOSE/DURATION :
780 umol/L
REFERENCE :
MUREAV Mutation Research. (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 1964- Volume(issue)/page/year: 221,263,1989

危害码 (欧洲) N
风险声明 (欧洲) R51/53:Toxic to aquatic organisms, may cause long-term adverse effects in the aquatic environment .
安全声明 (欧洲) S61
危险品运输编码 UN 3082
RTECS号 WM6250000

1.诺氟沙星为原料,经甲基化而得产品。


2.从诺氟沙星中的中间体硼螯合物开始制备。该硼螫合物、乙腈、N- 甲基哌嗪和三乙胺混合,室温反应后再回流。蒸除溶剂,加水,浓盐酸调至Ph=3后再回流。加入活性炭脱色,过滤。滤液碱化至Ph=11,再加活性炭脱色,过滤,用30%醋酸中和至Ph=6.7-7.2,冰箱中过夜。过滤,水洗,干燥得类白色的培氟沙星,收率82%,熔点270-272℃。培氟沙星溶入无水乙醇中,在60~70℃下滴加甲磺酸,反应。冷至15℃,过滤析出的结晶,用10倍乙醇重结晶,得甲磺酸培氟沙星,收率88.5%。

70458-92-3 preparation

3.也可硼螯合物、N-甲基哌嗪和三乙胺一起回流。再碱性水解,酸化至Ph=7.2,得培氟沙星;将其加入甲磺酸的水溶液中,反应得到的粗品用85%乙醇重结晶,得甲磺酸培氟沙星,收率79.4%,熔点284℃。